Zobrazeno 1 - 10
of 147
pro vyhledávání: '"Mamoru, Narukawa"'
Autor:
Takashi Sawada, Mamoru Narukawa
Publikováno v:
Cancer Control, Vol 31 (2024)
Background Combination therapy with multiple tyrosine kinase inhibitors (multi-TKIs) and immune checkpoint inhibitors (ICIs) has been increasingly tested in clinical studies. This study aimed to investigate the effect of the addition of ICI to multi-
Externí odkaz:
https://doaj.org/article/7a9a54301bfc4414a279b452031e73e8
Autor:
Yosuke Kubota, Mamoru Narukawa
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 18, Iss 1, Pp 1-7 (2023)
Abstract Background Randomized controlled trial (RCT) data have important implications in drug development. However, the feasibility and cost of conducting RCTs lower the motivation for drug development, especially for rare diseases. We investigated
Externí odkaz:
https://doaj.org/article/3c0d5f335d17437da9c86c13a8bc64f6
Autor:
Yoshihiro Oda, Mamoru Narukawa
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background In recent years, an increasing number of anticancer drugs have been approved based on the results of a single-arm trial (SAT). The magnitude of the objective response rate (ORR) in SATs is important for regulatory decisions, but t
Externí odkaz:
https://doaj.org/article/749f666805644fdeb78fbe462cc10df2
Autor:
Takashi Inoue MS, Mamoru Narukawa PhD
Publikováno v:
Cancer Control, Vol 29 (2022)
Background The clinical efficacy of immune checkpoint inhibitors (CPIs) has been proven; however, it is also known that their efficacy as monotherapy is limited, with a response rate of 20% or less in solid tumors. The combination of CPIs and antican
Externí odkaz:
https://doaj.org/article/1a9f40038f984a38a5ca87417badb317
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 3, Pp 1113-1122 (2021)
Abstract The current success rate of a drug candidate, from the beginning of the clinical trial to receiving marketing approval, is about 10%–20%, and it has not changed during the past few decades. Therefore, pharmaceutical companies are under pre
Externí odkaz:
https://doaj.org/article/6ea4b2a646974968962b49b49e22891f
Publikováno v:
Contemporary Clinical Trials Communications, Vol 24, Iss , Pp 100855- (2021)
Background: It is known that the success rates of phase III trials for solid cancers are low. The aim of this study was to investigate factors related to trial design and operation that were associated with the probability of the success of phase III
Externí odkaz:
https://doaj.org/article/9c58e45cd3cb41dfb50879775f916db7
Autor:
Yuko Hoshino, Mamoru Narukawa
Publikováno v:
Therapeutic Innovation & Regulatory Science. 56:839-847
Scientific information in the drug labeling is expected to be the most up-to-date and consistent information across countries where medicine is approved. The objective of the present study is to investigate the consistency of safety-related informati
Publikováno v:
Clinical Drug Investigation.
Autor:
Toshiyuki Tamai, Mamoru Narukawa
Publikováno v:
Investigational New Drugs.
Autor:
Yoshifumi Tachibana, Mamoru Narukawa
Background Existing studies and statistics on the drug lag between Japan and the United States (US) for anticancer drugs indicate that it has decreased, whereas more drugs are left unapproved in Japan. This study aimed to quantify the impact of unapp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27bdfd663f60edc3276f3338b25c70d0
https://doi.org/10.21203/rs.3.rs-2792303/v1
https://doi.org/10.21203/rs.3.rs-2792303/v1